{ "model": "qwen/qwen3.6-35b-a3b", "started_at": "2026-05-21T01:17:58.716Z", "system_prompt": "You are Analyst, the thesis-judgment stage of an AI trade-ideas pipeline.\n\nScout has already gathered a JSON dossier of scoring_inputs. Your job is to\nSCORE the dossier against the methodology rubric and either draft an idea\n(if score ≥ 60) or skip.\n\nOPTION B (skip) IS THE EXPECTED DEFAULT. The pipeline publishes rarely and\nonly when something clears a high bar. Most dossiers should return\n{ \"skip\": true, \"reason\": \"...\", \"score\": }. Mediocre publishes burn\nDevil's Advocate budget and create credibility risk on the public site.\n\nLOOK AT THE FULL STRUCTURE MENU. Even when Scout says 'no asymmetric long\nopportunity exists' (verdict=range_bound_or_income), there may be a clear\nINCOME structure (covered call against the high; strangle inside an IV-\nelevated band; CSP at a downside-defended strike). Don't reflex-skip just\nbecause long_stock isn't attractive. Read the dossier looking for what\nSHAPE OF TRADE fits, not just whether long is fits.\n\nSCORING RUBRIC (sum to max 100)\n\nA. SMART-MONEY CLUSTER (max 25) — from scoring_inputs.smart_money\n • 10 pts if 3+ distinct insiders with open-market purchases (code P) in\n last 90 days totaling ≥ $500K\n • +3 pts if CEO is among the buyers\n • +3 pts if CFO is among the buyers\n • +2 pts if total purchases > $5M\n • 5 pts for a known concentrated 13F initiation/add (Berkshire, Pershing\n Square, Appaloosa, Greenlight, Scion, Polen, Pabrai, Tepper, etc.)\n • +3 pts if it's in the manager's top-3 positions\n • 2 pts for politician STOCK Act recent buy\n • +1 pt if multiple unrelated members bought within 30 days\n • Penalty: −10 pts if material insider SELLING > BUYING in dollars\n\nB. OPTIONS FLOW / UOA (max 10) — from scoring_inputs.options_flow\n • 4 pts: whale_call_blocks_otm ≥ 2 with flow_directional_bias = bullish\n and flow_strength ∈ {moderate, strong}\n • 3 pts: bullish IV skew (call IV > put IV) consistent with thesis\n • 2 pts: net_dollar_bias_pct > 30 (sustained call-side flow)\n • 1 pt: large OI building at a defended price level\n • Penalty: −5 pts if whale_put_blocks_otm ≥ 2 and bias is bearish\n without a hedging explanation\n\nC. CATALYST (max 25) — from scoring_inputs.catalyst\n • 10 pts: earnings within 90 days AND last 4 quarters' EPS surprise > 0%\n • 8 pts: pending product launch / FDA / contract milestone in horizon\n • 5 pts: recent guidance raise (last 90 days)\n • 5 pts: quantifiable sector tailwind (named hyperscaler capex flowing\n to this name in $)\n Cap at 25 even if components add to more.\n\nD. MISPRICING (max 15) — from scoring_inputs.mispricing\n • 5 pts: forward P/E ≥ 20% below sector median (with non-deteriorating\n earnings)\n • 4 pts: EV/EBITDA ≥ 30% below sector median\n • 4 pts: FCF yield ≥ 7% with stable FCF\n • 5 pts: SOTP gap ≥ 25% (replaces one of the above)\n Cap at 15.\n\nE. QUALITY (max 15) — from scoring_inputs.quality\n • 5 pts: ROIC ≥ 15% (or trending there)\n • 5 pts: gross margin expanding ≥ 3pp YoY\n • 5 pts: net debt / EBITDA ≤ 2x (or net cash)\n\nF. MOMENTUM/TECHNICAL (max 10) — from scoring_inputs.technical\n • 3 pts: above both 50DMA and 200DMA\n • 4 pts: 12-1 month price return positive AND beating sector\n • 2 pts: RSI 14 in 40-65 zone\n • 1 pt: MACD bullish cross in last 30 days\n\nRISK CLASS — choose one based on the dossier's market_cap field:\n \"core\" — market_cap > $5B. Standard methodology sizing.\n \"asymmetric\" — market_cap ≤ $5B (small-cap moonshot). 90%+ of these\n bets lose money or go to zero; the few that work pay\n for the rest. Position sizing is far more conservative\n to fit the variance.\n\nTHRESHOLDS — depend on risk_class\n\n CORE risk_class:\n ≥ 80 Publish, confidence 5, position size cap 4-5%\n 70-79 Publish, confidence 4, position size cap 2.5-3.0%\n 60-69 Publish, confidence 3, position size cap 1.5-2.0%\n 50-59 Skip unless catalyst <30d + insider cluster\n < 50 Skip\n\n ASYMMETRIC risk_class — strict sizing:\n ≥ 80 Publish, confidence 5, position size cap 1.5%\n 70-79 Publish, confidence 4, position size cap 1.0%\n 60-69 Publish, confidence 3, position size cap 0.5%\n < 60 Skip (no exception; small caps need a clear catalyst)\n Structure must be long_stock (options structures are wrong shape for\n moonshots; Compliance enforces this in code).\n\nANTI-SIGNAL GATES (any one of these forces skip regardless of score):\n • Going-concern audit qualification\n • Pending material litigation (DOJ/SEC enforcement, class action with merit)\n • Customer concentration > 30%\n • Convertible/warrant overhang creating dilution > 10% of float\n • Accounting irregularities (restatements, auditor changes)\n • Avg daily volume < $5M (liquidity gate)\n • Pump-and-dump signals (sudden volume + chat-room mentions)\n\nIf scoring_inputs has anti_signals_present non-empty, treat each entry as a\ngate; skip unless you can articulate WHY it doesn't apply to this case.\n\nEDGE CHECK (philosophical, not numeric)\n\nAfter scoring, ask: \"What does this idea say that the market doesn't already\nknow?\" If the answer is generic (it's cheap, AI is a tailwind, technicals\nlook great), the score is misleading — skip even if numerical score is 65.\nReal edge means a specific data point or interpretation the market missed.\n\nSCOUT VERDICT → STRUCTURE GUIDANCE\n\nRead scoring_inputs and Scout's verdict together. The verdict tells you\nWHICH structures Scout thinks are in scope for this name:\n\n verdict='promising' → long_stock | csp (for asymmetric long)\n verdict='range_bound_or_income' → cc | strangle | csp on pullback\n (DON'T default to long_stock — Scout\n already said this isn't an asymmetric\n long. Look at IV elevated → strangle;\n stock at 52w high, fundamentals healthy\n → cc against implicit long; pullback\n thesis with cash → csp)\n verdict='bearish_setup' → naked_call (rarely; respect ceiling)\n\nIf Scout supplied structure_hints[], they're a starting point. You can\noverride with reasoning, but if you go OUTSIDE the verdict's natural set,\nexplain why in thesis_long.\n\nSTRUCTURE SELECTION — full menu:\n\n long_stock — multi-quarter asymmetric thesis, IV not elevated, want\n full upside participation\n csp — bullish, want to own at strike, IV elevated, ann yield ≥15%\n cc — range-bound or mildly bullish, IV elevated, on top of long\n stock leg, if-called return ≥15% ann\n strangle — RANGE-BOUND thesis with elevated IV. Sell OTM call + OTM\n put. Need: comfortable owning at put_strike, no parabolic\n upside expectation. Ann yield ≥12%. Compute and emit\n breakeven_high (call_strike + total_premium) and\n breakeven_low (put_strike - total_premium).\n naked_put — same setup as CSP but using margin. ~2x yield, margin call\n risk. Only for margin-equipped accounts. Note explicitly.\n naked_call — bearish setup with elevated IV. UNCAPPED loss if rally.\n Confidence ceiling 4 (Compliance enforces). Requires\n explicit upside-shock thesis + defense plan in conditions.\n\nMatch the structure to the thesis shape — don't reach for naked options\njust because the premium is fatter. Most candidates are best as long_stock\nor CSP. Strangles only when you have a clear range thesis backed by IV\nand fundamentals.\n\nIF YOU SKIP — output exactly:\n {\n \"skip\": true,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n }\n\nIF YOU PROCEED — output a draft idea matching this schema (this is the same\nschema the published site renders from):\n\n{\n \"skip\": false,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"draft\": {\n \"slug\": \"YYYY-MM-DD-symbol-keyphrase\",\n \"symbol\": \"TICKER\",\n \"company\": \"Full name\",\n \"sector\": \"semis-ai-infra\" | \"small-cap-asymmetric\",\n \"risk_class\": \"core\" | \"asymmetric\",\n \"headline\": \"Punchy 1-line — the news angle on the thesis\",\n \"thesis_short\": \"1 sentence — why this trade exists.\",\n \"thesis_long\": [\n \"Opening paragraph framing the setup.\",\n \"## Catalyst\",\n \"Detailed catalyst narrative.\",\n \"## Why the market is mispricing this\",\n \"Edge explanation, citing dossier facts.\",\n \"## Numbers\",\n \"- Bullet 1 with concrete numbers from the dossier\",\n \"- Bullet 2\",\n \"## Risk\",\n \"Honest description of what could go wrong.\"\n ],\n \"structure\": {\n \"type\": \"long_stock\" | \"csp\" | \"cc\" | \"strangle\" | \"naked_put\" | \"naked_call\",\n \"long_stock\": { \"entry_zone_low\": , \"entry_zone_high\": , \"shares_per_unit\": 100 },\n \"csp\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"if_assigned_basis\": },\n \"cc\": { \"underlying_basis\": , \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"if_called_return_pct\": },\n \"strangle\": { \"call_strike\": , \"put_strike\": , \"expiry\": \"YYYY-MM-DD\", \"call_premium_target\": , \"put_premium_target\": , \"total_premium_target\": , \"breakeven_high\": , \"breakeven_low\": , \"annualized_yield_pct\": , \"max_loss_note\": \"...\" },\n \"naked_put\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss_per_contract\": , \"margin_estimate_per_contract\": , \"warning\": \"...\" },\n \"naked_call\": { \"strike\": , \"expiry\": \"YYYY-MM-DD\", \"premium_target\": , \"annualized_yield_pct\": , \"max_loss\": \"UNLIMITED\", \"warning\": \"...\" }\n },\n \"entry\": {\n \"price_at_idea\": ,\n \"conditions\": \"How/when to enter — e.g., 'Open starter on pullback to MA50.'\"\n },\n \"exit\": {\n \"target_price\": ,\n \"time_horizon_months\": ,\n \"stop_conditions\": \"Specific signal(s) that trigger a close.\"\n },\n \"risk\": {\n \"bear_case\": \"Honest, specific bear case (not generic 'market could fall').\",\n \"what_breaks_thesis\": \"Specific event/data that invalidates the call.\",\n \"position_size_pct\": <0.5 to 5.0, conviction-weighted>\n },\n \"sources\": [\n { \"label\": \"...\", \"url\": \"...\" }\n ],\n \"confidence\": <1-5, conservative>,\n \"analyst\": \"research-desk\",\n \"scout_model\": \"minimax/minimax-m2.7\",\n \"analyst_model\": \"qwen/qwen3.6-35b-a3b\",\n \"devils_advocate_verdict\": null\n }\n}\n\nONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that\nsub-object. Leave the others null/omitted.\n\nALL NUMBERS must be drawn from the dossier or computable from it. Do not\ninvent prices, strikes, premiums.\n\nOUTPUT ONLY VALID JSON. No surrounding prose, no markdown fences.", "user_prompt": "Here is the dossier from Scout. Decide: skip or draft.\n\n\nLESSONS LEARNED: none yet.\n\nDOSSIER:\n{\n \"symbol\": \"OSCR\",\n \"company\": \"Oscar Health, Inc.\",\n \"investigation_summary\": \"Oscar Health reported a stunning Q1 2026 beat ($2.07 vs $1.10 estimate), more than doubling net income to $679M with revenue of $4.65B (+53% YoY). Membership grew to ~3.2M effectuated members (from 2.0M at year-end 2025) and medical loss ratio improved sharply. The stock hit a 5-year high near $25 in May 2026 following the print. However, both Form 4 filings triggering this investigation are SELL transactions under pre-arranged Rule 10b5-1 plans adopted February 12 — CFO Blackley liquidated ~210K shares at $23-25, and two directors received deferred stock units as compensation (not open-market buys). There is no genuine insider purchase cluster. The company appears operationally transformed with strong membership growth and margin expansion, but at current levels near the top of its historical range there is no clear mispricing edge — forward P/E ~17x sits in-line with health insurance peers rather than discounted to them. The stock is above both 50- and 200-DMAs, RSI at 69 is elevated, and implied volatility (70% ATM on June expiry) is high enough for income strategies but not indicative of an asymmetric long setup.\",\n \"verdict\": \"range_bound_or_income\",\n \"confidence_in_data\": 4,\n \"structure_hints\": [\n \"cc\",\n \"strangle\"\n ],\n \"business_snapshot\": \"Oscar Health is a ~$7B market cap health insurance technology company offering individual and family ACA marketplace plans, ICHRA products for employers, and a technology platform (+Oscar / Campaign Builder) serving both its own 3.2M members and external clients (nearly 0.6M client lives). The company has pivoted decisively from years of losses to profitability: Q1 2026 EPS of $2.07 vs $1.10 consensus, with operating income of $704M. Revenue grew 53% YoY to $4.65B driven by membership expansion — the company now operates in 20 states (up from 18 for 2025), with Florida and Texas as dominant markets representing ~75% of members. The business model is highly leveraged to ACA policy design: 93% of premiums come directly from CMS via APTC payments, making risk adjustment transfers a major P&L variable ($1.44B net payable in Q1 alone). Cash position is strong at $4.8B against only $482M debt (convertible notes), providing substantial capital cushion for ICHRA expansion and potential market share gains.\",\n \"scoring_inputs\": {\n \"smart_money\": {\n \"insider_open_market_purchases_90d\": [],\n \"insider_open_market_total_usd_90d\": 0,\n \"distinct_insider_buyers_90d\": 0,\n \"ceo_buy_present\": false,\n \"cfo_buy_present\": false,\n \"material_insider_selling_90d_usd\": 4900000,\n \"notable_13f_holders\": [\n \"pending — v2\"\n ],\n \"politician_recent_buys\": [\n \"pending — v2\"\n ]\n },\n \"catalyst\": {\n \"next_earnings_date\": \"2026-08-06\",\n \"recent_eps_surprise_pattern\": \"Q1 2026: $2.07 actual vs $1.10 estimate (+88% beat). Q4 2025: -$1.24 actual vs -$0.92 estimate (-35% miss — the loss quarter prior to the turnaround.\"\n },\n \"guidance_raise_in_last_90d\": true,\n \"named_catalysts\": [\n {\n \"type\": \"earnings\",\n \"description\": \"Q2 2026 earnings expected August 2026 with full-year guidance reaffirmation from Q1 print; consensus EPS ~$0.40 for Q2 — much smaller seasonal profit quarter vs Q1 due to claims seasonality in back half of policy year.\",\n \"date_or_window\": \"2026-08-06\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/oscar-health-announces-strong-financial-100000784.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"regulatory\",\n \"description\": \"CMS formally lowered ACA marketplace user fees — positive regulatory development reducing compliance burden for insurers.\",\n \"date_or_window\": \"2026-05-19\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/oscar-health-oscr-notches-5-020621518.html\"\n ],\n \"directional_bias\": \"bullish\"\n },\n {\n \"type\": \"guidance\",\n \"description\": \"Q1 2026 reaffirmation of full-year 2026 guidance — management signaled continued confidence in membership growth and margin trajectory.\",\n \"date_or_window\": \"2026-05-06\",\n \"source_urls\": [\n \"https://finance.yahoo.com/sectors/healthcare/articles/oscar-health-oscr-10-7-212212925.html\"\n ],\n \"directional_bias\": \"bullish\"\n }\n ]\n },\n \"mispricing\": {\n \"forward_pe\": 16.97,\n \"sector_median_forward_pe\": 17.5,\n \"ev_to_ebitda\": 18.58,\n \"sector_median_ev_to_ebitda\": 14,\n \"fcf_yield_pct\": 23.05,\n \"narrative\": \"OSCR trades roughly in-line with sector peers on forward P/E (~17x) despite having just posted a massive earnings beat and demonstrated operating leverage that historically was priced as loss-making entity. The stock has run from ~$10 lows (March 2026) to $25, leaving limited margin of safety for new entrants. FCF yield is high because the company generated $1.63B in FY2025 FCF but this is partly seasonal APTC timing dynamics — Q1 CMS payables swings are large.\"\n },\n \"quality\": {\n \"roic_pct\": null,\n \"gross_margin_trend_pp_yoy\": null,\n \"net_debt_to_ebitda\": -8.82,\n \"balance_sheet_grade\": \"A\"\n },\n \"technical\": {\n \"above_50dma\": true,\n \"above_200dma\": true,\n \"rsi_14\": 69.3,\n \"macd_recent_bullish_cross\": false,\n \"12_1_momentum_vs_sector_pct\": null\n },\n \"price_context\": {\n \"last_close\": 23.42,\n \"ytd_return_pct\": 20.54,\n \"from_52w_high_pct\": 8.43\n },\n \"filings_reviewed\": [\n {\n \"form\": \"10-K\",\n \"filed\": \"2026-02-13\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1568651/000156865126000011/oscr-20251231.htm\",\n \"key_takeaways\": [\n \"FY2025 revenue $13.3B (+53% YoY), near-profitability at -$39M net loss vs prior years of significant losses, membership 2.04M (up from 1.68M in 2024), expanded to 20 states for 2026, risk adjustment payable $2.59B as of year-end 2025, cash $2.77B vs debt $482M, MLR improvement trajectory documented\"\n ]\n },\n {\n \"form\": \"10-Q\",\n \"filed\": \"2026-05-07\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1568651/000156865126000040/oscr-20260331.htm\",\n \"key_takeaways\": [\n \"Q1 2026: $4.65B revenue (+53% YoY), net income $679M, operating income $704M vs $297M in Q1 2025; membership ~3.2M; medical loss ratio improvement driving profitability; risk adjustment payable $2.73B; cash $4.8B; strong operational leverage from technology platform\"\n ]\n },\n {\n \"form\": \"4\",\n \"filed\": \"2026-05-20\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1568651/000152502026000009/xslF345X06/wk-form4_1779308229.xml\",\n \"key_takeaways\": [\n \"CFO Blackley sold 110,000 shares on May 18 at $25.03 weighted avg via Rule 10b5-1 plan adopted Feb 12, 2026\"\n ]\n },\n {\n \"form\": \"4\",\n \"filed\": \"2026-05-18\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1568651/000152502026000007/xslF345X06/wk-form4_1779135348.xml\",\n \"key_takeaways\": [\n \"CFO Blackley sold ~91K+9K shares on May 14 at $23.10-$23.79 weighted avg via Rule 10b5-1 plan adopted Feb 12, 2026\"\n ]\n },\n {\n \"form\": \"4\",\n \"filed\": \"2026-04-13\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1568651/000150906626000002/xslF345X06/wk-form4_1776111398.xml\",\n \"key_takeaways\": [\n \"Director Sid Sankaran received 1,203 deferred stock units as director compensation in lieu of cash retainer at $14.54/share\"\n ]\n },\n {\n \"form\": \"4\",\n \"filed\": \"2026-04-13\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1568651/000195488326000007/xslF345X06/wk-form4_1776111371.xml\",\n \"key_takeaways\": [\n \"Director William Gassen received 1,418 deferred stock units as director compensation in lieu of cash retainer at $14.54/share\"\n ]\n }\n ],\n \"options_context\": {\n \"expiries_examined\": [\n \"2026-05-22\",\n \"2026-06-26\"\n ],\n \"iv_summary\": \"ATM IV ~70% on June expiry (36 DTE); elevated enough for premium capture via covered calls or short straddles/strangles; 10 delta put OI at $15.50 (1000 contracts) is distant protective positioning, not near-term bearish signal\",\n \"notable_skew_or_flow\": \"Call volume dominates put volume by ~2.4x on net dollar basis (+$52K directional bias). Top call OI strike: 22.5 with 1210 contracts — this is the key resistance level to watch for covered-call writers.\"\n },\n \"competitive_landscape\": \"Oscar competes in ACA individual market against national carriers (UnitedHealth, CVS/Aetna), regional Blue Cross plans, and Medicaid-focused insurers expanding into marketplace products. Key differentiator is its full-stack technology platform enabling member engagement, lower administrative costs, and +Oscar B2B revenue from Campaign Builder. Membership growth (+21% 2024 to 2025) outpacing many peers in the individual market segment.\",\n \"key_risks\": [\n \"ACA policy risk: eAPTC expiration or regulatory changes to marketplace rules could materially impact membership and premium economics\",\n \"Risk adjustment volatility: $1.44B Q1 net payable; adverse development in prior-year transfers creates significant earnings uncertainty\",\n \"High member concentration: Florida (58% of members) exposes the company to single-state regulatory and market dynamics\",\n \"Medical cost trend uncertainty: Q1 is seasonally favorable; back-half claims typically accelerate as deductibles are met, creating margin compression risk\",\n \"Regulatory environment: ongoing changes to ACA interpretation, minimum MLR requirements, state-by-state licensing\"\n ],\n \"what_the_market_might_be_missing\": \"Nothing material. Oscar's transformation from loss-making startup to profitable health insurer was well-documented through 2025 earnings and Q1 2026 confirmed the trajectory. The stock has already re-rated dramatically (from $10-$11 in March 2026 to $25). At current levels near 52-week highs with RSI elevated at 69, the market is not missing anything — it is fully pricing in continued execution.\",\n \"anti_signals\": [\n \"concentration\",\n \"dilution\"\n ],\n \"sources\": [\n {\n \"label\": \"OSCR Q1 2026 earnings release\",\n \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/oscar-health-announces-strong-financial-100000784.html\"\n },\n {\n \"label\": \"OSCR Q1 beat coverage\",\n \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/oscar-health-oscr-10-7-212212925.html\"\n },\n {\n \"label\": \"CMS user fee reduction news\",\n \"url\": \"https://finance.yahoo.com/sectors/healthcare/articles/oscar-health-oscr-notches-5-020621518.html\"\n },\n {\n \"label\": \"Form 4 - CFO Blackley May 18 sale\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1568651/000152502026000009/xslF345X06/wk-form4_1779308229.xml\"\n },\n {\n \"label\": \"Form 4 - CFO Blackley May 14 sales\",\n \"url\": \"https://www.sec.gov/Archives/edgar/data/1568651/000152502026000007/xslF345X06/wk-form4_1779135348.xml\"\n }\n ],\n \"unfetched_signals\": [\n \"13f_deltas\",\n \"politician_trades\",\n \"sentiment_score\"\n ]\n}\n\nOutput ONLY the decision JSON described in the system prompt. Do NOT\ninclude ... reasoning blocks — they eat the output token\nbudget and produce truncated, unparseable decisions.", "completions": [ { "ts": "2026-05-21T01:18:53.071Z", "raw_content": "The dossier is for OSCR (Oscar Health, Inc.).\nScout verdict: `range_bound_or_income`\nMarket cap: ~$7B -> Core risk class.\nScoring:\nA. Smart-Money Cluster: 0 pts. No insider purchases. Material insider selling > buying ($4.9M). Penalty -10 pts. Score: 0 (or -10, capped at 0).\nB. Options Flow / UOA: IV is high (~70% ATM on June expiry). Call volume dominates put volume by ~2.4x. No specific whale call blocks mentioned. Score: 2 pts (net_dollar_bias > 30%? The dossier says \"+$52K directional bias\" but doesn't give a clear pct. I'll give 1 pt for elevated IV / call dominance, or 0. Let's say 1 pt).\nC. Catalyst: Next earnings Aug 6, 2026. Last quarter beat by 88%. But prior quarter missed. No guidance raise in last 90d? Wait, dossier says `guidance_raise_in_last_90d: true`. But Q1 was May 6. So yes. Score: 5 pts.\nD. Mispricing: Forward P/E 16.97 vs sector 17.5. In-line. EV/EBITDA 18.58 vs sector 14. Higher. FCF yield 23.05% but seasonal. No clear mispricing edge. Score: 0 pts.\nE. Quality: ROIC null. Gross margin null. Net debt/EBITDA -8.82 (net cash). Score: 5 pts.\nF. Momentum: Above 50DMA and 200DMA. RSI 69 (elevated, not 40-65). MACD not bullish cross. 12-1 momentum null. Score: 3 pts.\n\nTotal Score: ~11/100.\nAnti-signals: concentration (Florida 58%), dilution (convertible notes).\nEdge check: \"Nothing material. Oscar's transformation... was well-documented... stock has already re-rated... market is not missing anything\".\nVerdict: Skip.\nReason: The stock has already re-rated 150% from March lows to 52-week highs, trading in-line with peers on forward multiples with no clear catalyst or mispricing edge. Heavy insider selling and elevated RSI further negate income or long setups at current levels.\nStructure: Skip.\n\nLet's double check scoring rubric.\nA: 0 (selling penalty applies, but score can't go below 0 usually, or I'll just put 0).\nB: 1\nC: 5\nD: 0\nE: 5\nF: 3\nTotal: 14.\nWell below 60. Skip.\n\nOutput format:\n{\n \"skip\": true,\n \"score\": 14,\n \"score_breakdown\": { ... },\n \"reason\": \"...\"\n}\nCheck constraints: \"ONLY ONE STRUCTURE TYPE.\" -> skip format is specified.\n\"Output ONLY the decision JSON described in the system prompt.\"\nI will produce the skip JSON.\nScore breakdown: smart_money: 0, options_flow: 1, catalyst: 5, mispricing: 0, quality: 5, technical: 3.\nReason matches the edge check and anti-signals.\nReady. \nLet's verify risk class: >$5B -> core.\nThresholds: <50 Skip.\nAll good.\nOutput matches exactly. \nProceed. \nSelf-Correction/Refinement during thought: \nCheck A penalty: \"Penalty: −10 pts if material insider SELLING > BUYING in dollars\". I'll put 0 for smart_money.\nCheck B: IV is high, call dominance. 1 pt is fair.\nCheck C: Guidance raise true. 5 pts.\nCheck D: P/E in line, EV/EBITDA higher. 0 pts.\nCheck E: Net cash. 5 pts.\nCheck F: Above DMAs. 3 pts.\nTotal: 14.\nReason: \"The stock has already re-rated 150% from March lows to a 52-week high, trading in-line with sector peers on forward multiples with no identifiable mispricing edge. Heavy insider selling and elevated RSI further negate both long and income setups at current levels.\"\nMatches requirements. Output matches schema.\nProceeds. \nOutput Generation. \n```json\n{\n \"skip\": true,\n \"score\": 14,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 1,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 3\n },\n \"reason\": \"The stock has already re-rated 150% from March lows to a 52-week high, trading in-line with sector peers on forward multiples with no identifiable mispricing edge. Heavy insider selling and elevated RSI further negate both long and income setups at current levels.\"\n}\n```\nWait, let's verify the prompt's exact skip format:\n {\n \"skip\": true,\n \"score\": <0-100 composite>,\n \"score_breakdown\": {\n \"smart_money\": <0-25>, \"options_flow\": <0-10>, \"catalyst\": <0-25>,\n \"mispricing\": <0-15>, \"quality\": <0-15>, \"technical\": <0-10>\n },\n \"reason\": \"1-2 sentences why this dossier doesn't support a thesis.\"\n }\nMatches exactly.\nI will output this JSON.\nOne minor point: The prompt says \"Output ONLY the decision JSON described in the system prompt. Do NOT include reasoning blocks\". I will strictly follow that.\nAll good. \nProceeds. \n[Output Generation] -> *Self-Correction/Verification during generation prep*: \nCheck scoring inputs for catalyst: `guidance_raise_in_last_90d: true` -> 5 pts. \nCheck scoring inputs for quality: `net_debt_to_ebitda: -8.82` -> 5 pts. \nCheck scoring inputs for technical: `above_50dma: true, above_200dma: true` -> 3 pts. \nCheck scoring inputs for mispricing: `forward_pe: 16.97`, `sector_median: 17.5` -> 0 pts. \nCheck scoring inputs for smart_money: `material_insider_selling_90d_usd: 4900000` -> 0 pts. \nCheck scoring inputs for options_flow: `iv_summary: ATM IV ~70%`, `call volume dominates put volume by ~2.4x` -> 1 pt. \nTotal: 14. \nReason is solid. \nReady. \nOutput matches. \nProceeds. \n[Done] \n*Self-Correction/Note during thought*: The prompt says \"ONLY ONE STRUCTURE TYPE. Pick long_stock, csp, OR cc and only fill that sub-object. Leave the others null/omitted.\" This applies to the PROCEED case. For SKIP, it gives a specific schema. I will follow the SKIP schema.\nAll good.\nOutput matches exactly.\nProceeds. \n[Final Check of the Prompt]: \"IF YOU SKIP — output exactly: { ... }\"\nI will output exactly that.\nDone. \n[Output Generation] -> *Proceeds*\n\n\n{\n \"skip\": true,\n \"score\": 14,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 1,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 3\n },\n \"reason\": \"The stock has already re-rated 150% from March lows to a 52-week high, trading in-line with sector peers on forward multiples with no identifiable mispricing edge. Heavy insider selling and elevated RSI further negate both long and income setups at current levels.\"\n}", "cleaned_content": "{\n \"skip\": true,\n \"score\": 14,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 1,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 3\n },\n \"reason\": \"The stock has already re-rated 150% from March lows to a 52-week high, trading in-line with sector peers on forward multiples with no identifiable mispricing edge. Heavy insider selling and elevated RSI further negate both long and income setups at current levels.\"\n}", "tool_calls": null, "finish_reason": "stop" } ], "tool_results": [], "final_message": "{\n \"skip\": true,\n \"score\": 14,\n \"score_breakdown\": {\n \"smart_money\": 0,\n \"options_flow\": 1,\n \"catalyst\": 5,\n \"mispricing\": 0,\n \"quality\": 5,\n \"technical\": 3\n },\n \"reason\": \"The stock has already re-rated 150% from March lows to a 52-week high, trading in-line with sector peers on forward multiples with no identifiable mispricing edge. Heavy insider selling and elevated RSI further negate both long and income setups at current levels.\"\n}", "tool_calls_total": 0, "walltime_ms": 54355, "stop_reason": "stop", "completed_at": "2026-05-21T01:18:53.071Z" }